Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
- Resource Type
- Article
- Source
- In
Research and Practice in Thrombosis and Haemostasis August 2021 5(6) - Subject
- Language
- ISSN
- 2475-0379